华兰生物：公司研发的重组 Exendin-4-FC融合蛋白注射液已顺利完成 I 期/II 期临床研究

Core Viewpoint - The company has successfully completed Phase I/II clinical trials for its recombinant Exendin-4-FC fusion protein injection, which is a treatment for type 2 diabetes, and is preparing to initiate Phase III clinical trials [1] Group 1: Product Development - The company is developing a new indication for its drug targeting overweight/obesity and has submitted a registration communication to the National Medical Products Administration, which has been accepted [1]